313 active not recruiting. 313 Phase 2, 76 Phase 1, 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 313 | Active not recruiting 313 |
| Phase 1 | 76 | Active not recruiting 76 |
| Phase 3 | 16 | Active not recruiting 16 |
Follow Endocrine System Diseases: new trials by email Literature Review of Endocrine System Diseases trials Research Report on Endocrine System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes Insulin Isophane Human, NPH, Pre-emptive Algorithm, Triamcinolone Acetonide Knee Injection - Diabetes Mellitus, Type 2, Hyperglycemia Due to Type 2 Diabetes Mellitus | Phase 1 / Phase 2 | Active not recruiting | Shifa International Hospital | 125 | 2026-08-10 | 2026-09-15 |
| A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity AT673 low dose, AT673 high dose, Placebo - Adults With Overweight/Obesity and Type 2 Diabetes | Phase 2 | Active not recruiting | Antag Therapeutics | 150 | 2026-06-19 | 2026-09-29 |
| Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes - Type 2 Diabetes | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2026-06-15 | 2026-08-27 |
| A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism HRS-1780 Tablets, Placebo - Primary Aldosteronism | Phase 2 | Active not recruiting | Shandong Suncadia Medicine Co., Ltd. | 61 | 2026-04-23 | 2026-10-13 |
| A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents SHR-3167 Injection, SHR-3167 Injection Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 102 | 2026-04-11 | 2026-06-04 |
| Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i ARBs alone, ARBs in combination of SGLT2i - Proteinuria, Diabetes (DM) | Phase 2 / Phase 3 | Active not recruiting | Dr Mudassar Saeed Pansota | 60 | 2026-04-06 | 2026-05-14 |
| Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity KAI-7535, Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Kailera | 306 | 2026-04-06 | 2026-09-09 |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets icovamenib 100mg, Placebo - Type 2 Diabetes | Phase 2 | Active not recruiting | Biomea Fusion Inc. | 64 | 2026-03-27 | 2026-08-28 |
| A Clinical Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Premature Ovarian Insufficiency YT023, Control Arm (Conventional Therapy) - Premature Ovarian Insufficiency | Phase 1 / Phase 2 | Active not recruiting | International Peace Maternity and Child Health Hospital | 60 | 2026-03-20 | 2026-04-03 |
| GRK-Biased Activation Via β2-Adrenergic Receptors in Human Skeletal Muscle ATR-258 - Overweight and Obesity | Phase 2 | Active not recruiting | Morten Hostrup, PhD | 13 | 2026-02-19 | 2026-10-14 |
| Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC SKB264, Clarithromycin - Ovarian Epithelial Cancer | Phase 2 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 20 | 2026-01-16 | 2026-06-01 |
| Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) NP-G2-044, PLD - Platinum-resistant Ovarian Cancer | Phase 2 / Phase 3 | Active not recruiting | Novita Pharmaceuticals, Inc. | 380 | 2025-12-29 | 2026-03-09 |
| TRPM8 Activators for Peripheral Neuropathy Hand and Foot Mask - CIPN - Chemotherapy-Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy (DPN) | Phase 2 | Active not recruiting | SHIANG-SUO HUANG | 60 | 2025-11-03 | 2026-05-15 |
| Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes Metformin Hcl 850Mg Tab, Lifestyle Intervention, Enhanced Lifestyle Intervention - Weight Loss, Gestational Diabetes Mellitus in Pregnancy | Phase 2 | Active not recruiting | George Washington University | 41 | 2025-10-27 | 2026-11-06 |
| A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) Navlimetostat, Gemcitabine, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 470 | 2025-10-23 | 2026-06-03 |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen - Diabetic Kidney Disease (DKD), Type 2 Diabetes | Phase 2 | Active not recruiting | Beijing University of Chinese Medicine | 15 | 2025-10-20 | 2026-11-02 |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes Macupatide, Eloralintide, Macupatide Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Eli Lilly and Company | 200 | 2025-10-16 | 2026-10-09 |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin LY3938577, Degludec - Diabetes Mellitus, Type 2 | Phase 2 | Active not recruiting | Eli Lilly and Company | 100 | 2025-10-13 | 2026-07-13 |
| Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old Crinecerfont - Congenital Adrenal Hyperplasia | Phase 2 | Active not recruiting | Neurocrine Switzerland GmbH | 7 | 2025-09-30 | 2026-08-28 |
| Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT Prehabilitation - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Case Comprehensive Cancer Center | 1 | 2025-09-05 | 2026-09-15 |
Showing 20 of 313. Sign in to see all of them.
Pancreatic Neoplasms (87) · Ovarian Neoplasms (78) · Fallopian Tube Neoplasms (35) · Diabetes Mellitus, Type 2 (31) · Thyroid Neoplasms (27) · Diabetes Mellitus, Type 1 (23) · Carcinoma, Non-Small-Cell Lung (22) · Colorectal Neoplasms (19) · Carcinoma, Ovarian Epithelial (17) · Stomach Neoplasms (17) · Diabetes Mellitus (16) · Breast Neoplasms (15) · Endometrial Neoplasms (15) · Melanoma (14) · Neoplasm Metastasis (14)
Neoplasms by Site (207) · Endocrine Gland Neoplasms (204) · Neoplasms (201) · Urogenital Diseases (124) · Female Urogenital Diseases and Pregnancy Complications (122) · Female Urogenital Diseases (120) · Digestive System Diseases (117) · Digestive System Neoplasms (111) · Gonadal Disorders (103) · Urogenital Neoplasms (102) · Genital Diseases (100) · Pancreatic Diseases (96) · Genital Diseases, Female (95) · Adnexal Diseases (94)
pembrolizumab (32) · Gemcitabine (28) · Albumin-Bound Paclitaxel (18) · Magnetic Resonance Spectroscopy (18) · Nivolumab (17) · 130-nm albumin-bound paclitaxel (16) · Specimen Handling (15) · Taxes (15) · olaparib (15) · Cisplatin (13) · Biopsy (12) · Carboplatin (12) · Paclitaxel (12) · Bevacizumab (11) · Cyclophosphamide (11)
National Cancer Institute (NCI) (20) · M.D. Anderson Cancer Center (16) · Memorial Sloan Kettering Cancer Center (9) · Eli Lilly and Company (7) · Mayo Clinic (7) · Massachusetts General Hospital (6) · AbbVie (5) · AstraZeneca (5) · University Health Network, Toronto (5) · BioMarin Pharmaceutical (4) · Hoffmann-La Roche (4) · CanariaBio Inc. (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University of Chicago (3)
United States (221) · Canada (46) · Spain (38) · Australia (33) · China (33) · United Kingdom (32) · France (28) · South Korea (26) · Italy (25) · Germany (24) · Japan (20) · Belgium (14) · Poland (13) · Puerto Rico (13) · Taiwan (12)
Denise L Faustman, MD, PhD (3) · Amit Oza, M.D. (2) · Eric Sherman, MD (2) · MD Verastem (2) · Maria E Cabanillas (2) · Meredith McKean, MD, MPH (2)
PMID 31401903, PMID 31838007, PMID 37934000, PMID 40086048, PMID 10024506, PMID 10433086, PMID 10605821, PMID 10852253, PMID 11208527, PMID 11564949, PMID 11815483, PMID 12972423, PMID 15972654, PMID 16011702, PMID 16714282, PMID 17214730, PMID 1730582, PMID 17524725, PMID 18176934, PMID 18360702, PMID 19111249, PMID 19188144, PMID 19763038, PMID 19968980, PMID 19997760, PMID 20127992, PMID 20405312, PMID 20501948, PMID 20956533, PMID 21147316, PMID 21389784, PMID 22442300, PMID 23250488, PMID 24327518, PMID 25403204, PMID 25481791, PMID 25554012, PMID 26397425, PMID 26586415, PMID 27424289, PMID 28053024, PMID 28114552, PMID 28324110, PMID 28672195, PMID 28841916, PMID 2891995, PMID 29118225, PMID 29223478, PMID 29383130, PMID 29506054
2023 (11), 2015 (5), U10CA180868 (5), 2019 (3), P50CA136393 (3), U10CA180820 (3), U10CA180821 (3), 2017 (2), 2018 (2), 2025 (2), N01CM00032 (2), N01CM00071 (2), P30CA008748 (2), U10CA180886 (2), U10CA180888 (2)